Aptinyx Inc. (APTX): Price and Financial Metrics

Aptinyx Inc. (APTX): $0.10

0.00 (3.11%)

POWR Rating

Component Grades








Add APTX to Watchlist
Sign Up

APTX Price/Volume Stats

Current price $0.10 52-week high $0.72
Prev. close $0.09 52-week low $0.01
Day low $0.09 Volume 231,100
Day high $0.10 Avg. volume 1,317,051
50-day MA $0.07 Dividend yield N/A
200-day MA $0.08 Market Cap 6.50M

APTX Stock Price Chart Interactive Chart >

Aptinyx Inc. (APTX) Company Bio

Aptinyx Inc. develops therapeutics for neurological disorders. The company is focused on the development of drugs that interact with the NMDA receptor, and the company says it will use the funds to advance drugs for chronic pain, post-traumatic stress disorder (PTSD) and cognitive impairment in Parkinson’s disease. The company was founded in 2015 and is based in Evantson, Illinois.

APTX Latest News Stream

Event/Time News Detail
Loading, please wait...

APTX Latest Social Stream

Loading social stream, please wait...

View Full APTX Social Stream

Latest APTX News From Around the Web

Below are the latest news stories about APTINYX INC that investors may wish to consider to help them evaluate APTX as an investment opportunity.

Horizon (HZNP) Q1 Earnings and Revenues Miss Estimates

Horizon Therapeutics (HZNP) reports lower-than-expected first-quarter 2023 results as it misses the Zacks Consensus Estimates for both revenues and earnings.

Yahoo | May 3, 2023

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data

Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

Yahoo | April 18, 2023

Agenus (AGEN) Rises on Fast Track Tag for Cancer Combo Drug

The FDA grants Fast Track Designation to Agenus' (AGEN) phase II study evaluating the botensilimab/balstilimab combination in non-MSI-H colorectal cancer patients. The stock jumps 16% following the news.

Yahoo | April 18, 2023

Adaptimmune (ADAP) Up 7%, Gets T-Cell Programs Rights From GSK

Adaptimmune Therapeutics (ADAP) enters into a transition deal with GSK to regain rights to its proprietary T-cell therapy programs. Shares of the company surges 7% following the news.

Yahoo | April 12, 2023

Merck (MRK) Keytruda Studies in Difficult-to-Treat Cancers Fail

Merck (MRK) and Eisai announce the discontinuation of the phase III LEAP-003 study seeking approval of the Keytruda and Lenvima combo. Another phase III LEAP-017 study fails to meet goals.

Yahoo | April 10, 2023

Read More 'APTX' Stories Here

APTX Price Returns

1-mo N/A
3-mo N/A
6-mo 55.52%
1-year -20.00%
3-year -96.32%
5-year -97.27%
YTD 4.17%
2023 -66.35%
2022 -89.31%
2021 -22.83%
2020 1.17%
2019 -79.32%

Continue Researching APTX

Want to see what other sources are saying about Aptinyx Inc's financials and stock price? Try the links below:

Aptinyx Inc (APTX) Stock Price | Nasdaq
Aptinyx Inc (APTX) Stock Quote, History and News - Yahoo Finance
Aptinyx Inc (APTX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!